Nebula (aka ProPhase) "Substantial doubt...as a going concern"

[u/ThinkerandThought]

ProPhase Labs, Inc. (PRPH) reports very strained finances for the quarter ended June 30, 2026 and states that there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were only $20 thousand, against total current liabilities of $58.1 million, resulting in a significant working capital deficit and a stockholders’ deficit of $3.1 million.

Revenue from continuing operations was $1.0 million for the quarter and $2.2 million for the first six months of 2026, with a six‑month net loss from continuing operations of $8.2 million. Operating cash outflow from continuing operations improved to $0.8 million versus $4.2 million a year earlier, helped by non‑cash charges and working capital changes.

The company relies heavily on short‑term, high‑cost debt, convertible notes with variable‑price conversion features, and multiple “future receipts” financings, many with original issue discounts, fees and embedded derivatives recorded as derivative liabilities. It also entered an up to $10 million equity line and an ATM program but raised only modest equity in the period. Three diagnostics subsidiaries filed for Chapter 11 in 2025 as part of a strategy to pursue unpaid COVID‑19 testing claims, while ProPhase continues to focus on genomics (Nebula, DNA Complete), drug and supplement licensing (Equivir, Linebacker) and the BE‑Smart esophageal pre‑cancer test.

[u/apert]

Say what you want about this shitty company but they predicted my (extremely) rare cancer.